MILPITAS, Calif., March 2, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the Company's President and Chief Executive Officer will provide a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 14 at 2:05 pm ET. The conference is being held at the Loews Miami Beach Hotel in Miami, Florida.
A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at http://investors.protagonist-inc.com.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways for which there are marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer preferential drug exposure in the gastrointestinal tissue compartment, the potential for improved safety due to minimal exposure in the blood, improved convenience and compliance, and potentially an opportunity for the earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's oral peptide product candidates, PTG-100 and PTG-200, are based on this approach with the potential to transform the existing treatment paradigm for IBD, which includes both ulcerative colitis and Crohn's disease.
Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical development staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-barclays-global-healthcare-conference-300416662.html
SOURCE Protagonist Therapeutics, Inc.